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Summary statement: 
Validation of Pegasus-OCT, an artificial intelligence based software for the automated detection            
of macula disease from OCT scans, is conducted on independent, multi-centre data. 5,588             
volumes spanning multiple populations, device manufacturers and acquisition sites were          
assessed. Pegasus-OCT achieves AUROCs of >98% on AMD, DME and general anomaly            
detection.  
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Abstract 
Purpose: ​To evaluate Pegasus-OCT, a clinical decision support software for the identification of             
features of retinal disease from macula OCT scans, across heterogenous populations involving            
varying  patient demographics, device manufacturers, acquisition sites and operators. 
Methods: 5,588 normal and anomalous macular OCT volumes (162,721 B-scans), ​acquired at            
independent centres in five countries, were processed using the software. Results were            
evaluated against ground truth provided by the dataset owners. 
Results: ​Pegasus-OCT performed with AUROCs of at least 98% for all datasets in the detection               
of general macular anomalies. For scans of sufficient quality, the AUROCs for general AMD and               
DME detection were found to be at least 99% and 98%, respectively.  
Conclusions: The ability of a clinical decision support system to cater for different populations               
is key to its adoption. Pegasus-OCT was shown to be able to detect AMD, DME and general                 
anomalies in OCT volumes acquired across multiple independent sites with high performance.            
Its use thus offers substantial promise, with the potential to alleviate the burden of growing               
demand in eye care services caused by retinal disease.  
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Introduction 
More than 250 million people globally are currently estimated to be living with moderate to               
severe visual impairment or blindness​1​. That figure is predicted to double by 2040 due to the                
projected increase in population growth and ageing​2​. This places a significant burden on             
healthcare services. Despite there being over 200,000 ophthalmologists worldwide, there is           
currently a significant shortfall of practitioners in developing countries. Furthermore, although           
the number of ophthalmologists is increasing in developed countries, the population aged above             
60 years is growing at twice the rate of the profession​3​. Prompt and substantive steps are                
therefore needed to alleviate the current and anticipated deficit of expertise.  
 
Diseases of the macula such as age-related macular degeneration (AMD) and diabetic macular             
edema (DME) constitute some of the main causes of avoidable sight loss in developed nations.               
The prevalence of AMD, for instance, was 170 million people in 2016​4​, projected to increase to                
196 million in 2020, and further to 288 million by 2040​5​. These diseases manifest as anatomical                
changes to the macula such as the development of drusen, retinal pigment epithelium             
detachments, and the build up of subretinal and/or intraretinal fluid. The identification of these              
characteristics is crucial to both detection and to treatment management​6,7,8​. 
 
Optical coherence tomography (OCT) imaging is currently the most frequently used imaging            
modality in the evaluation of macular disease, with over 30 million scans taken per year​9​. For                
the diagnosis of AMD, a 70-fold increase in the use of OCT has been recorded since its                 
introduction​10 and it has additionally become a critical tool for the baseline retinal evaluation              
needed to guide administration of therapy​11,12​.  
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OCT imaging is now widely regarded as the gold standard for guiding the diagnosis and               
treatment of AMD and DME. However, the resulting rapid expansion in imaging data generated              
has not been matched by the availability of trained experts to interpret these scans accurately.               
Computer-aided diagnosis (CAD) has the potential to alleviate the human and economic burden             
of disease detection. Recently, CAD systems that utilise Artificial Intelligence (AI) in particular             
have gained prominence, for instance in the detection of Diabetic Retinopathy (DR) from fundus              
photographs​13,14​. However, the use of AI CAD systems for the analysis of OCT image data has                
so far been less explored.  
 
The applicability of AI in ophthalmic diagnosis has become particularly propitious since the             
development of a method known as deep learning​15,16​. ​Deep learning uses convolutional neural             
networks to process grid-based data such as images, and has been observed to be particularly               
successful in automated imaging diagnostics​17​. A deep learning algorithm aims to mimic the way              
the human expertise is developed for the same task by discovering image features that              
distinguish normal from pathological classes. These features are then used to classify new             
images when the algorithm is applied. However, a potential risk is that poor or unexpected               
performance may occur if the data used to train the algorithm inadequately captures the              
diversity of patients and images present in real world scenarios​18​. While humans can generalise              
knowledge learned on one set of images to others which may have very different appearances,               
deep learning algorithms are prone to overfitting or bias resulting from limited variation in              
training data​19​. A thorough evaluation of any algorithm is therefore necessary before adoption in              
clinical practice. 
 
In the interpretation of ophthalmic images using deep learning, the largest body of work to date                
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has been in the detection of DR from fundus photographs​20,21,22,23​. The use of these methods in                
clinical practice has also been shown in retrospective trials to provide significant reduction in the               
manual burden and costs of screening for DR​24,25​. Although research in OCT analysis is more               
incipient, papers released in recent years have shown promising results​26,27,28,29,30​.  
 
The largest scale prior investigations​28,29,30 evaluate their algorithms on 1000-2151 OCT           
volumes. However, common to all the above algorithms is a concern that results are presented               
on evaluation sets which are from the same cohorts as those that the algorithms were trained                
on. Questions therefore remain as to how these algorithms would perform on examples from              
cohorts external to the training set​18​. To date, none of the algorithms in the papers described                
above have been made available by their authors for external evaluation. 
 
In the case of OCT it has been shown that, even in the absence of disease, variations in                  
ethnicity, age and gender can result in statistically significant differences in the appearance of              
retinal structures​31,32​. In addition, imaging variation due to the acquisition device needs to be              
accounted for.  
 
This paper provides an evaluation of Pegasus-OCT, a commercial AI based system for the              
detection of retinal diseases from OCT images of the macula. In contrast to prior work in the                 
field, the evaluation is conducted on independent datasets spanning a range of acquisition sites              
and scanner types, on a total of 5,588 OCT cube volumes (162,721 B-scans). To the best of                 
our knowledge, it represents the first evaluation of deep learning based algorithms for OCT              
image interpretation on data originating from populations that have not in any way been utilised               
in creating the algorithms.  
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 Methods 
Automated Disease Detection 
Pegasus-OCT v1.0 is a clinical decision support system for detecting disease from OCT scans              
of the macula developed by, and available from Visulytix Ltd (Visulytix, London, UK), currently              
for investigational purposes. Using deep learning technologies, the software identifies images           
showing anomalous features in the macula which could be indicative of disease. In addition,              
specific features indicative of Dry AMD, Wet AMD and DME are also identified. This system               
produces four independent classifications in line with the guidelines outlined by the National             
Institute of Clinical Excellence​33​: 
1. General anomaly (e.g. presence of signs of unspecified pathology or anomalous 
features) 
2. ‘Dry’ AMD incorporating signs of early and atrophic AMD (e.g. presence of drusen, 
pigmentary abnormalities, uncomplicated pigment epithelial detachments or geographic 
atrophy) 
3. ‘Wet’ AMD incorporating active and inactive neovascular AMD (e.g. presence of intra- or 
sub-retinal fluid, along with fibrovascular/serous PED and/or signs of Dry AMD) 
4. DME (e.g. presence of hyper reflective foci, retinal thickening, and intra- and /or 
sub-retinal fluid) 
 
Pegasus-OCT reports a score for each of these categories, showing the likelihood of features of               
these pathologies being present. Features may be common to more than one category; for              
instance, features of Dry AMD (such as drusen) are often also visible in patients with Wet AMD.                 
The detection of drusen may therefore result in a high score for both of these categories if other                  
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features of Wet AMD (such as fluid) are also present. An additional classification of General               
AMD, obtained by pooling Wet and Dry predictions, is therefore also presented in this paper.  
 
Deep Learning Models 
The four classifiers used are all binary classifiers which utilise the same VGG16 convolutional              
neural network model​34​. Details of the network architecture and training details are given in              
Supplemental Digital Content 1. These models have been trained on OCT data acquired from              
different manufacturers and using a range of imaging protocols. Before training, all images are              
normalised to have the same size and intensity range. In addition, to increase generalisability,              
significant image augmentation is used during training. At each training epoch, images are read              
in with a random rotation, translation, zoom and brightness enhancements applied. This means             
that the model never sees the same image twice during training and serves to enlarge the range                 
of training data. Finally, to prevent overfitting to the training data, early stopping is used​19​. These                
extensions enable the application of the classifiers to images acquired from different scanners             
and with differing B-scan resolutions.  
 
Image Quality Assessment 
An automated strategy for disease detection requires images of sufficient quality to reliably             
visualise retinal anatomy. Poor contrast, extensive noise, or artifacts may conceal the presence             
of real pathology or may be confused for abnormalities in otherwise normal scans. We              
therefore also verify the quality of each B-scan in terms of suitability for automated disease               
detection. This is done via a deep learning method which classifies scans as being either               
‘gradable’ or ‘ungradable’. An overall quality rating is then reported for each dataset, reflecting              
the percentage of gradable B-scans in the dataset.  
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 Performance Evaluation 
In this paper, the results of Pegasus-OCT in classifying each of the four categories are               
evaluated on five external datasets. These datasets were acquired independently of the            
Pegasus-OCT manufacturer as well as independently of each other. Local ethical committee            
approval was obtained for each dataset where required. The datasets span geographic            
locations and multiple acquisition sites, and were acquired with a range of protocols and              
scanners. A summary of the datasets used in the evaluation of Pegasus-OCT is shown in Table                
1. Where available, demographic information is given in Supplemental Digital Content 2. An             
example image from each dataset can be seen in Figure 1.  
 
Images from these datasets were run through the Pegasus-OCT software with the operator             
masked to ground truth diagnoses. The results of Pegasus-OCT were then compared to the              
provided ground truth at a whole volume level. However, for dataset A1, whole macular volumes               
were not made available for assessment. Instead, ground truth is provided for each individual              
B-scan in the dataset and so the results are assessed at a B-scan level in this case only.  
 
All classifiers are run on all images which report a probability of anomaly or pathology for each                 
of the four cases. The classification of General Anomaly is based solely on the probability of this                 
classifier exceeding a specified threshold, where the same threshold is applied across all             
datasets. For the pathology classes, if only one classifier yields a probability above the relevant               
threshold, the subject is classified with that pathology. However there are cases in which two or                
more classifiers report probabilities above the required threshold. In the case of Wet and Dry               
AMD being present, the volume will always be classified as Wet AMD. Where both AMD and                
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DME are present, the classification will be assigned to that with the highest probability. It should                
be noted that while this allows quantitative evaluation of the algorithms, having all probabilities              
available to a user in a clinical setting may be helpful in the assessment of complex cases.  
 
The performance of Pegasus-OCT was evaluated by calculating the area under the curve of the               
receiver operating characteristic (AUROC) curves as in comparable work​28,29,30 . The AUROC is             
a measure of the diagnostic ability of a predictor in a binary classification. It gives the probability                 
that the classifier will rank a randomly chosen pathological instance higher than a randomly              
chosen instance without that pathology. 
 
Datasets from Public Sources 
Dataset A1​29 consists of 108,309 macula OCT images from 4,686 patients acquired on             
Heidelberg Spectralis OCT scanners. These images consist of individually-labelled B-scans          
only; whole volumes were not available. Subjects were taken from retrospective cohorts of adult              
patients from the Shiley Eye Institute of the University of California San Diego, the California               
Retinal Research Foundation, Medical Center Ophthalmology Associates, the Shanghai First          
People’s Hospital, and Beijing Tongren Eye Center between July 1, 2013 and March 1, 2017. All                
OCT imaging was performed as part of patients’ routine clinical care. There were no exclusion               
criteria based on age, gender, or race. Further details of the demographics of the cohort can be                 
found in Supplemental Digital Content 2. It should be noted that the mean ages of normal and                 
pathological cases differ significantly and this should be considered when assessing results.            
Local electronic medical record databases for diagnoses were searched and each 2D B-scan             
image was then graded by a tier of graders including four ophthalmologists and two senior               
retinal specialists. This dataset was used by the authors to detect patients requiring urgent              
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referral and observational cases. However, due to the difference in labelling between this             
dataset and the Pegasus-OCT pathology classification, this dataset is only used for the             
evaluation of General Anomalies.  
 
Dataset A2​35 consists of 384 cases (AMD and Normal Controls). Volumetric scans with             
non-unique acquisition protocols were acquired from four SD-OCT clinics (Devers Eye Institute,            
Duke Eye Center, Emory Eye Center and National Eye Institute, USA), on Bioptigen OCT              
scanners. Subjects were recruited from the AREDS2 Clinical Trial NCT00734487. The A2A            
SDOCT study recruited AMD subjects from the AREDS 2 study population at 4 AREDS 2 Study                
Centers. Controls were recruited from Duke University Eye Center and Emory University.            
Subjects included were AMD subjects and controls, men and women between the ages of 50               
and 85 years. The AMD subjects had macular status ranges from large drusen in both eyes or                 
large drusen in one eye and advanced AMD (neovascular AMD or geographic atrophy) in the               
fellow eye. Subjects were excluded only if the ocular media was not clear enough to allow good                 
fundus photography. 
 
Dataset A3​36 consists of 148 cases with a distribution of 50 normal controls, 48 Dry AMD, and                 
50 DME, acquired at Noor Eye Hospital in Tehran on Heidelberg SD-OCT imaging systems.              
These data contains varying number of both A-scans (512 or 768) and B-scans (range 19-61).               
No further demographic information is available.  
 
Datasets from Private Sources 
Dataset B1 consists of 25 DME, 25 Dry AMD, 25 Wet AMD, and 25 normal controls, imaged on                  
Heidelberg SD-OCT devices. Anonymisation was conducted at source. Subjects from each           
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category were selected at random from routine clinical care from the Ophthalmica clinic in              
Thessaloniki, Greece. 
 
Dataset B2 consists of 135 eyes acquired on a Topcon 3D-OCT 1000 device (B2a) and the                
same 135 eyes acquired on a Zeiss Cirrus HD-OCT 5000 device (B2b) at the School of                
Optometry and Vision Sciences, Cardiff University. Macular volumes from each device           
comprised 512x128 scans. Ground truth was established using a modified AREDS classification            
system, incorporating OCT images. Colour fundus photos and OCT images were presented in             
conjunction, and classified by two experienced clinicians. Any disagreements were classified by            
a third observer and discussed by all three to reach a final classification. Demographic data for                
this cohort are given in Supplemental Digital Content 2.  
 
Results  
 
Results of the evaluation of Pegasus-OCT on all datasets are shown in Table 2. The Quality                
Rating is an automated assessment of the percentage of B-scans in each dataset deemed to be                
of sufficient quality for automated grading. The same threshold for quality was used across all               
datasets.  
 
For the purposes of this paper, evaluation was conducted on all images regardless of quality.               
Accuracy, sensitivity, specificity and AUROC results were reported at a whole macular volume             
level, using ground truth provided by the dataset owners. For dataset A1 only, volume-level              
labels were not available. However, all 108,309 B-scans were individually labelled by the             
providers, and so the metrics are evaluated on a B-scan level in this case. All accuracy,                
sensitivity and specificity results have been reported at the same threshold on the ROC curve               
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for all datasets. Actual ROC curves can be found in Supplemental Digital Content 3.  
 
In distinguishing between normal and abnormal scans, Pegasus-OCT performs at an AUROC of             
over 98% for every dataset. In datasets with quality ratings of above 50%, the minimum               
AUROCs obtained for the detection of general AMD and DME were found to be 99% and 98%,                 
respectively. Lower performance was observed when the image quality of the B-scans was             
deemed to be insufficient for automated grading. It should be noted that ground truth for               
datasets such as B2 were obtained using clinical information in addition to the OCT volume               
presented. 
  
 
Discussion 
 
Clinical decision support systems for the analysis of macula OCT scans offer substantial             
promise. Such systems can be agile and their performance adjusted for the specific integration              
in workflow. For example, in a screening context, specificity could be increased to avoid              
unnecessary false positives which can burden secondary care​25​. Similarly they have the            
potential to be deployed at scale and therefore at low cost, thus benefiting healthcare              
providers​24​.  
 
Crucial to the translation of algorithms from theory to the clinic is the idea of generalisability. An                 
algorithm needs to perform well on data acquired from a variety of populations, devices,              
operators and protocols. The power of deep learning algorithms lies in their flexibility and              
capacity to encode very large and complex amounts of information. However, this also makes              
deep learning algorithms particularly vulnerable to bias stemming from the data they are trained              
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on (overfitting), which can result in catastrophic failures when applied in the real world​18,37​.              
Despite this, even the most notable publications have only evaluated their algorithms on             
subjects from the same populations as those on which they were trained. While providing              
promising preliminary results, the extrapolation of the stated performance of these algorithms to             
more diverse data sources cannot - and must not - be assumed.  
 
In contrast, this paper conducts an evaluation of Pegasus-OCT on purely external datasets,             
which were not used in the creation of the algorithms. It represents validation of an AI system                 
on the largest and most diverse OCT data to date, to the best of our knowledge, with data                  
acquired from multiple sites in five different countries analysed. The heterogeneity of the             
datasets used aims to address any potential selection biases. A comparison of the evaluation              
datasets used in the work presented here and in pertinent prior work is shown in Table 3. 
 
The results show promising performance of Pegasus-OCT. Evaluation has been conducted on            
large datasets from multiethnic populations, without any specific optimisation. Accuracy,          
sensitivity and specificity analysis was conducted at a common threshold on the ROC curve              
across all datasets. Improved performance is likely to be obtained when the cut-off point on the                
ROC curve is chosen specifically to optimise the characteristics of a particular clinical site.  
 
These results presented in this paper are comparable to those of prior related work in Table 3.                 
In the separation of Normal and AMD patients, an AUROC of 93.8% for classification of macula                
cube volumes and 97.5% when multiple volumes from the same patient were combined for an               
overall diagnosis was reported​28​. Dataset A1 was used to distinguish between urgent referrals             
and observation cases with a resulting AUROC of 99.9%​29​. Most recent work​30 reported             
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AUROCs for disease detection of 99.5% and individual pathology detection ranges between            
96.6% to 100%. The key difference is that these papers use between 80-99% of their cohort                
data to train their algorithms, with the evaluation conducted on the remaining subjects in the               
cohort.  
 
While the results presented in this paper have been evaluated on data from a range of external                 
sources, the distribution of scanner manufacturer used is still unbalanced. The majority of data              
have been evaluated on Heidelberg scanners which also show the best performance. However,             
these datasets were also assessed to have the highest quality scans. Further work is needed to                
disambiguate the influence of scanner manufacturer and image quality in the performance of             
Pegasus-OCT.  
 
The study presented evaluated defined datasets including normal, wet, dry AMD and DME.             
Other disease types, such as Macular/Lamellar Hole, Epiretinal Membrane (ERM) were not            
explicitly labelled in the datasets and so were not independently assessed in this version of the                
platform. However signs of these may have been present in images of other pathology (such as                
Dry AMD with ERM).  
 
As the datasets were mainly taken from trials or secondary care, the prevalence of the diseases                
evaluated in this paper are likely to be lower and milder in a screening setting. However, by                 
adjusting sensitivity and specificity thresholds, performance can be tailored to suit the intended             
use of the software. This opens up exciting and transformative opportunities to utilise OCT in               
non-specialist settings, with subsequent work required to determine the health economic effects            
of such system implementation. Furthermore, the use of such commercially available platforms            
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has the potential to assist clinicians in managing the exponential demand in eye care services               
caused by retinal disease. 
 
Acknowledgements 
Prof. Tom H. Margrain and Prof. Rachel V. North at the School of Optometry and Vision                
Sciences, Cardiff University, for their contribution to the acquisition and classification of Dataset             
B2. 
 
Funding: ​This study was funded by Visulytix Ltd. 
 
 
References 
 
[1] World Health Organization, Global Data on Visual Impairments 2010, 2012 
 
[2] Bourne RRA, Flaxman SR, Braithwaite T, et al.; Vision Loss Expert Group. Magnitude, 
temporal trends, and projections of the global prevalence of blindness and distance and near 
vision impairment: a systematic review and meta-analysis. Lancet Glob Health. 2017 
Sep;5(9):e888–97. 
 
[3] Resnikoff S, Felch W, Gauthier T-M, Spivey B. The number of ophthalmologists in practice 
and training worldwide: a growing gap despite more than 200 000 practitioners. Br J 
Ophthalmol. 2012;96(6):783-787. 
 
[4] Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): 
associations with cardiovascular disease phenotypes and lipid factors. Eye and Vision 2016; 
3:34.  
 
[5] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and 
disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet 
Global Health 2014; Feb 2(2):e106-16 
 
[6] Keane PA, Liakopoulos S, Jivrajka RV,  et al. Evaluation of optical coherence tomography 
retinal thickness parameters for use in clinical trials for neovascular age-related macular 
degeneration. Invest Ophthalmol Vis Sci. 2009; 50(7):3378-3385. 
 
[7] Reznicek L, Muhr J, Ulbig M, et al. Visual acuity and central retinal thickness: fulfilment of 
retreatment criteria for recurrent neovascular AMD in routine clinical care. Br J Ophthalmol. 
2014; 98(10):1333-1337. 
16 
 
[8] Pron G. Optical coherence tomography monitoring strategies for A-VEGFetreated 
age-related macular degeneration: an evidence-based analysis. Ont Health Technol Assess 
Ser. 2014; 14(10):1-64. [online]. 
http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/ontario-health-tecno
logy-assessment-series/OCT-monitoring-strategies. 
 
[9] Fujimoto J, Swanson E. The Development, Commercialization, and Impact of Optical 
Coherence Tomography. Invest Ophthalmol Vis Sci. 2016; 57(9): OCT1–OCT13. 
 
[10] Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991; 
254(5035):1178e1181. 
 
[11]  Keane PA, Patel PJ, Liakopoulos S, et al. Evaluation of age-related macular degeneration 
with optical coherence tomography. Surv Ophthalmol. 2012; 57(5):389-414. 
 
[12] Ilginis T, Clarke J, Patel PJ. Ophthalmic imaging. Br Med Bull. 2014; 111(1):77-88. 
 
[13] van Ginneken B, Schaefer-Prokop CM, Prokop M. Computer-aided diagnosis: how to move 
from the laboratory to the clinic. Radiology. 2011; 261(3):719-732. 
 
[14] van der Heijden AA, Abramoff MD, Verbraak F, et al. Validation of automated screening for 
referable diabetic retinopathy with the IDx-DR device in the Hoorn Diabetes Care System. Acta 
Ophthalmol. 2018; 96(1):63-68. 
 
[15] Krizhevsky A, Sutskever I, Hinton G. ImageNet classification with deep convolutional 
networks. NIPS'12 Proceedings of the 25th International Conference on Neural Information 
Processing Systems - Volume 1, 2012; 1097-1105. 
 
[16] Kavukcuoglu K, Sermanet P, Boureau Y-L, et al. Learning convolutional feature hierarchies 
for visual recognition. NIPS'10 Proceedings of the 25th International Conference on Neural 
Information Processing Systems 2010; 1090-1098. 
 
[17] Litjens G, Kooi T, Ehteshami Bejnordi B, et al. A survey on deep learning in medical image 
analysis. Medical Image Analysis, 2017; 42:60-88. 
 
[18] Zech JR, Badgeley MA, Liu M, et al. Variable generalization performance of a deep learning 
model to detect pneumonia in chest radiographs: A cross-sectional study. PLoS Med 2018; 
15(11): e1002683.  
 
[19] Caruana R, Lawrence S, Giles L. Overfitting in neural nets: backpropagation, conjugate 
gradient, and early stopping. NIPS'00 Proceedings of the 13th International Conference on 
Neural Information Processing Systems, 2000;381-387. 
17 
 
[20] Abràmoff M, Lou Y, Erginay A, et al. Retina Improved Automated Detection of Diabetic 
Retinopathy on a Publicly Available Dataset Through Integration of Deep Learning. Invest 
Ophthalmol Vis Sci. 2016; 57(13):5200-5206. 
 
[21] Ting DSW, Cheung CYL, Lim G et al. Development and Validation of a Deep Learning 
System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From 
Multiethnic Populations With Diabetes. JAMA. 2017;318(22):2211-2223. 
 
[22] Gulshan V, Peng L, Coram M, et al. Development and Validation of a Deep Learning 
Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. JAMA. 2016; 
316(22):2402-2410 
 
[23] Gargeya R, Leng T. Automated Identification of Diabetic Retinopathy Using Deep Learning. 
Ophthalmology. 2017; 124(7):962-969 
 
[24] Ribeiro L, Oliveira CM, Neves C, et al. Screening for Diabetic Retinopathy in the Central 
Region of Portugal. Added Value of Automated 'Disease/No Disease' Grading. Ophthalmologica 
2015; 233:96-103. 
 
[25] Tufail A, Rudisill C, Egan C, et al. Automated Diabetic Retinopathy Image Assessment 
Software: Diagnostic Accuracy and Cost-Effectiveness Compared with Human Graders. 
Ophthalmology 2017; 124(3):343-351. 
 
[26]  Treder M, Lauermann JL, Eter N, Automated detection of exudative age-related macular 
degeneration in spectral domain optical coherence tomography using deep learning. Graefes 
Arch Clin Exp Ophthalmol. 2018; 256, 259–265. 
 
[27] Schlegl T, Waldstein SM, Bogunovic H, et al. Fully automated detection and quantification 
of macular fluid in OCT using deep learning. Ophthalmology 2018; 125, 549–558. 
 
[28] Lee CS, Baughman DM, Lee AY. Deep Learning Is Effective for Classifying Normal versus 
Age-Related Macular Degeneration Optical Coherence Tomography Images. Ophthalmology 
Retina 2017; 1(4):322-327. 
 
[29] Kermany D, Goldbaum M, Cai W, et al. Identifying Medical Diagnoses and Treatable 
Diseases by Image-Based Deep Learning. Cell, 2018; 172:122-1131. 
 
[30] De Fauw J, Ledsam J, Romera-Paredes B, et al. Clinically applicable deep learning for 
diagnosis and referral in retinal disease. Nature Medicine 2018; 24:1342–1350. 
 
[31] Kashani AH, Zimmer-Galler IE, Shah SM. Retinal thickness analysis by race, gender, and 
age using Stratus OCT. Am J Ophthalmol. 2010; 149(3):496-502. 
18 
 
[32]  Ooto S, Hangai M, Yoshimura N. Effects of sex and age on the normal retinal and 
choroidal structures on optical coherence tomography. Curr Eye Res. 2015; 40(2):213-25. 
 
[33] National Institute for Health and Care Excellence (2018) Tuberculosis (NICE Guideline 82). 
Available at: ​https://www.nice.org.uk/guidance/ng82/resources​  [Accessed October 2018] 
 
[34] Simonyan K, Zisserman A. Very Deep Convolutional Networks for Large-Scale Image 
Recognition. International Conference on Learning Representations, 2015.  
 
[35] Farsiu S, Chiu SJ, O’Connell RV, et al. Quantitative Classification of Eyes with and without 
Intermediate Age-related Macular Degeneration Using Optical Coherence Tomography. 
Ophthalmology 2014; 121(1):162-172. 
 
[36] Rasti R, Rabbani H, Mehridehnavi A, Hajizadeh F. Macular OCT Classification using a 
Multi-Scale Convolutional Neural Network Ensemble. IEEE Trans. Med. Im. 2018; 
37(4):1024-1034 
 
[37] Buolamwini J, Gebru T. Gender Shades: Intersectional Accuracy Disparities in Commercial 
Gender Classification. Conference on Fairness, Accountability, and Transparency. Proceedings 
of Machine Learning Research 2018; 81:1–15. 
 
 
 
 
 
  
19 
 
 
 
Table 1:​ Independent evaluation datasets used in this paper 
Name Acquisition device 
manufacturer(s) 
Countries Number of 
acquisitio
n Sites 
Number of 
eyes 
Source 
A1 Heidelberg SD-OCT USA 
China 
3 
2 
4,686 Public​29  
A2 Bioptigen SD-OCT USA 4 384 Public​35  
A3 Heidelberg SD-OCT Iran 1 148 Public​36  
B1 Heidelberg SD-OCT Greece 1 100 Private 
B2 a) Topcon 3D-OCT 
1000 
b) Zeiss Cirrus 
HD-OCT 5000 
UK 1 135 
 
135 
Private 
Total 
number 
4 unique manufacturers 5 12 5,588  
None of the images in these datasets were used in the development of Pegasus-OCT. 
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Table 2​: Results of Pegasus-OCT evaluation showing Area under Receiver Operating 
Characteristic (ROC) curve, Accuracy (Acc), sensitivity (Se) and specificity (Sp) of detection​. 
Reported figures correspond to evaluation on a whole OCT volume level, unless otherwise 
stated.  
 
 
 
Number 
of OCT 
volumes 
(slices) 
Performance 
General 
Anomaly  
General 
AMD 
Dry AMD Wet 
AMD 
DME Quality 
Rating 
(%) 
 
A1 
(Heidelberg 
SD-OCT) 
Shiley Eye 
Institute of the 
UCDS (USA), 
California Retinal 
Research 
Foundation 
(USA), Medical 
Center 
Ophthalmology 
Associates, 
Shanghai First 
People’s 
Hospital, (China) 
Beijing Tongren 
Eye Center 
(China) 
4,686 
(108,309) 
 
ROC: 
0.99* 
Acc: 0.96 
Se: 0.94 
Sp: 0.98 
 
    94 
A2 ​(Bioptigen 
SD-OCT) 
Devers Eye 
Institute, Duke 
Eye Center, 
Emory Eye 
Center and 
National Eye 
Institute (USA) 
384 
(38,382) 
ROC: 0.98 
Acc: 0.91 
Se: 0.98 
Sp: 0.71 
ROC: 0.89 
Acc: 0.89 
Se: 0.93 
Sp: 0.79 
   14 
A3 
(Heidelberg 
SD-OCT) 
Noor Eye 
Hospital, Tehran 
(Iran) 
148 
(2,960) 
ROC: 0.99 
Acc: 0.94 
Se: 0.92 
Sp: 0.98 
ROC: 0.99 
Acc: 0.95 
Se: 0.96 
Sp: 0.95 
ROC: 0.98 
Acc: 0.94 
Se: 0.96 
Sp: 0.93 
 
 ROC: 0.98 
Acc: 0.93 
Se: 0.96 
Sp: 0.91 
89 
B1 
(Heidelberg 
SD-OCT) 
Ophthalmica 
Ophthalmology 
100 
(12,800) 
ROC: 1.00 
Acc: 0.98 
Se: 1.00 
Sp: 0.92 
R: 0.999 
Acc: 0.96 
Se: 1.00 
Sp: 0.92 
 
ROC: 0.99 
Acc: 0.94 
Se: 1.00 
Sp: 0.92 
ROC: 0.98 
Acc: 0.96 
Se: 0.96 
Sp: 0.96 
ROC: 
0.998 
Acc: 0.96 
Se: 0.96 
Sp: 0.96 
89 
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and Microsurgery 
Institute (Greece) 
B2a 
(Topcon 
3D-OCT 
1000) 
School of 
Optometry and 
Vision Sciences, 
Cardiff University 
(UK) 
135 
(17,280) 
ROC: 0.99 
Acc: 0.96 
Sens: 0.95 
Spec: 0.96 
ROC: 0.98 
Acc: 0.87 
Se: 0.99 
Sp: 0.64 
ROC: 0.85 
Acc: 0.71 
Se: 0.86 
Sp: 0.66 
ROC: 
0.86 
Acc: 0.87 
Se: 0.89 
Sp: 0.87 
 49 
B2b 
(Zeiss Cirrus 
HD-OCT 
5000) 
School of 
Optometry and 
Vision Sciences, 
Cardiff University 
(UK) 
135 
(17,280) 
ROC: 0.99 
Acc: 0.95 
Se: 0.95 
Sp: 0.94 
ROC: 0.99 
Acc: 0.95 
Se: 0.95 
Sp: 0.94 
ROC: 0.83 
Acc: 0.76 
Se: 0.80 
Sp: 0.74 
 
ROC: 
0.93 
Acc: 0.85 
Se: 0.91 
Sp: 0.82 
 
 87 
* AUROC evaluated at B-scan level, not whole volume level 
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Table 3:​ Evaluation datasets used in deep learning methods for OCT classification 
Publication Testing set 
acquisition sites 
and scanners 
Testing set size  
(3D OCT volumes 
unless otherwise 
stated) 
Testing set data 
sources used in 
training? 
(% of cohort data 
used for training) 
De Fauw et al. 2018​30  ● Moorfields, UK 
(Heidelberg) 
● Moorfields, UK 
(Topcon) 
1,113 ✔ All 
(93% of all data) 
Kermany et al. 2018​29  ● Shiley Eye Institute 
of the UCDS, USA 
● California Retina 
Research 
Foundation, USA 
● Medical Center 
Ophthalmology 
Associates, USA 
● Shanghai First 
People’s Hospital, 
China 
● Beijing Tongren 
Eye Center, China 
(All Heidelberg) 
1,000  
(2D slices) 
✔ All  
(99% of all data) 
Lee et al. 2017​28  U. Washington 
(Heidelberg) 
2,151 ✔All  
(80% of all data) 
This paper ● Shiley Eye Institute 
of the UCDS, USA 
● California Retina 
Research, 
Foundation, USA 
● Medical Center 
Ophthalmology 
Associates, USA 
● Shanghai First 
People’s Hospital, 
China  
● Beijing Tongren 
Eye Center, China 
(All Heidelberg) 
● Ophthalmica 
Institute, Greece 
(Heidelberg) 
5,588 ✘ None 
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● Noor University 
Hospital, Tehran, 
Iran (Heidelberg) 
● Devers Eye 
Institute, USA  
● Duke Eye Center, 
USA  
● Emory Eye Center, 
USA 
● National Eye 
Institute, USA 
(All Bioptigen) 
● Cardiff University, 
UK (Zeiss) 
● Cardiff University, 
UK (Topcon) 
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Figure 1: ​Example images from each dataset evaluated 
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